A trial of lenalidomide and rituximab for follicular lymphoma or marginal zone lymphoma (AUGMENT)
Cancer type:
Status:
Phase:
This trial looked at adding lenalidomide to rituximab for follicular or marginal zone lymphoma. It was for people whose lymphoma had got worse or come back despite treatment.
The trial was open for people to join between 2014 and 2015. The team published the results in 2019.
More about this trial
When this trial was done, doctors usually treated follicular lymphoma or marginal zone lymphoma that had come back with rituximab and chemotherapy. Sometimes the lymphoma came back again. Doctors often gave more rituximab on its own if that happened.
Researchers wanted to find out if having lenalidomide as well as rituximab might work better. When this trial was done, lenalidomide was already being used for some types of lymphoma and myeloma.
Lenalidomide works in several ways. It:
- stops the signals that cancer cells use to divide and grow
- helps the
immune system 
to recognise cancer cells - stops the cancer developing new blood vessels
This was a phase 3 trial. People taking part were put into a treatment group at random. They either had:
- rituximab and lenalidomide
- rituximab and a dummy drug (placebo)
The main aims of the trial were to find out:
- how well the combination of rituximab and lenalidomide works
- more about the side effects of having lenalidomide and rituximab together
Summary of results
As part of our editorial policy, any trial information we write is checked externally before we put it on our website. The research team have published some results for this trial. But we have been unable to find anyone involved with the trial to check the summary for us.
This means we are not able to include a plain English summary of the results on this page.
More information
There is more information about this trial in the link to the medical journal below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
John P. Leonard and others
Journal of Clinical Oncology, 2019. Volume 37, issue 14, pages 1188 – 1199.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor John Gribben
Supported by
Celgene Corporation
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
